文献速递泌尿生殖MR

基于磁共振成像的前列腺癌早期诊断筛查方案设计:Sapienza前列腺癌二次筛查随机对照试验(PROSA)的初步结果

Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
PubMed 文献 · Eur Radiol · 2023-08-10

PROSA为前瞻性随机单中心研究,将351名男性随机分为A组(175人,无论PSA值均行bpMRI)和B组(按临床实践,PSA升高61人行bpMRI,PSA正常112人不筛查),MRI阳性者行MR引导靶向活检。A组检出4例临床显著前列腺癌,B组未检出(p=0.046),EER为3.6%、CER为1.2%、ARR为2.5%、NNT为40.3,提示非增强MRI作为筛查工具有前景。

要点

  • A组无论PSA值均行bpMRI,检出4例临床显著前列腺癌,B组未检出,p=0.046。
  • 筛查效率指标:EER 3.6%、CER 1.2%、ARR 2.5%、NNT 40.3。
  • 非增强MRI作为前列腺癌早期筛查工具可能有助于减少不必要穿刺及临床不显著癌检出。

核心结论

  • PROSA初步数据提示非增强MRI作为前列腺癌早期检测筛查工具具有前景,尚需进一步数据验证最合适的筛查方案。

诊断标准与关键数值

  • 以bpMRI筛查阳性后行MR引导靶向活检为参考,A组检出4例临床显著前列腺癌,B组未检出,p=0.046;EER 3.6%、CER 1.2%、ARR 2.5%、NNT 40.3。

临床应用与阅片要点

  • 本研究比较非增强MRI与PSA检测作为前列腺癌二次预防筛查试验,MRI阳性者转诊行MR引导靶向活检。

局限性

  • 原文结论指出需进一步数据验证最合适的筛查方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The main objective is to propose an MRI-based screening protocol, investigating the role of MRI without the injection of contrast media (bi-parametric MRI, bpMRI) as a secondary prevention test for prostate cancer (PCa) early diagnosis, comparing MRI with the prostate specific antigen (PSA) test. For this reason, preliminary results of Prostate Cancer Secondary Screening in Sapienza (PROSA) are presented, to investigate the efficiency of an MRI-based screening protocol. PROSA is a prospective, randomized, single-center study. To date, 351 men have been enrolled and blindly randomized into two different arms: (A) Men underwent a bpMRI regardless of their PSA values (175); (B) Men followed as per clinical practice: those with increased PSA (61) were referred to bpMRI, while those with normal PSA (112) were not. Men who screened positive on MRI were directed to MR-directed targeted biopsy. On arm A, 4 clinically significant PCa have been detected, while none was found on arm B (p = 0.046). To evaluate the efficiency of the screening protocol, we calculated the experimental event rate (EER, 3.6%), control event rate (CER, 1.2%.), absolute risk reduction (ARR, 2.5%), and number needed to treat (NNT, 40.3). PROSA represents an interesting experience in the field of imaging-based PCa screening. The preliminary data from this trial highlight the promising role of non-contrast MRI as a screening tool for early detection of PCa. Further data will finally validate the most appropriate screening program.

CLINICAL RELEVANCE STATEMENT: PROSA depicts an interesting experience in the field of research focused on imaging-based prostate cancer screening. Its preliminary data highlight the promising role of non-contrast MRI as a screening tool for early detection of PCa.

KEY POINTS: • Promotion of an MRI-based screening protocol, investigating the role of non-contrast MRI as a secondary prevention test for prostate cancer early diagnosis, comparing MRI with PSA test. • Prostate Cancer Secondary Screening in Sapienza (PROSA) represents an interesting experience in the field of research focused on imaging-based prostate cancer screening; its preliminary results indicate that it is possible to use non-contrast MRI as a screening tool for early detection of PCa. • This new approach to PCa screening could facilitate the early diagnosis of clinically significant prostate cancer while reducing the number of unnecessary prostate biopsies and the detection of clinically insignificant prostate cancer.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Messina E, La Torre G, Pecoraro M, et al. Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA). Eur Radiol. 2023. PMID: 37561183. doi:10.1007/s00330-023-10019-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。